Bank of New York Mellon’s Intelligent Bio Solutions INBS Stock Holding History

Bank of New York Mellon’s Portfolio INBS Stock Details INBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-13	Closed	-$78K	–	4644
2021 Q3	$78K	Buy	+13	New	+$99.7K	﹤0.01%	4375

Other funds holding INBS

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

WealthShield Partners Cary, North Carolina $898M AUM 19.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Bank of New York Mellon's INBS Position: Q4 2021 in Review

Bank of New York Mellon sold out of Intelligent Bio Solutions (INBS) in Q4 2021, closing a stake of 13 shares — an estimated $78K sold.

Bank of New York Mellon first reported a position in INBS in Q3 2021 and held it in 1 quarter. The position peaked at $78K in Q3 2021. 8 funds tracked by Wall St. Rank hold INBS as of Q4 2021.

Bank of New York Mellon reported no remaining Intelligent Bio Solutions position as of Q4 2021 after selling out during the quarter.
Bank of New York Mellon sold 13 Intelligent Bio Solutions shares in Q4 2021, an estimated $78K.
Bank of New York Mellon first reported a position in Intelligent Bio Solutions in Q3 2021 and held it in 1 quarter.
Bank of New York Mellon's Intelligent Bio Solutions position peaked at $78K in Q3 2021.
8 funds tracked by Wall St. Rank held Intelligent Bio Solutions as of Q4 2021.

Based on Bank of New York Mellon's 13F filing for Q4 2021, filed 11 Feb 2022.